Literature DB >> 21900571

Fukutin-related protein alters the deposition of laminin in the eye and brain.

Mark R Ackroyd1, Charlotte Whitmore, Sarah Prior, Manuja Kaluarachchi, Margareta Nikolic, Ulrike Mayer, Francesco Muntoni, Susan C Brown.   

Abstract

Mutations in fukutin-related protein (FKRP) are responsible for a common group of muscular dystrophies ranging from adult onset limb girdle muscular dystrophies to severe congenital forms with associated structural brain involvement. The defining feature of this group of disorders is the hypoglycosylation of α-dystroglycan and its inability to effectively bind extracellular matrix ligands such as laminin α2. However, α-dystroglycan has the potential to interact with a number of laminin isoforms many of which are basement membrane/tissue specific and developmentally regulated. To further investigate this we evaluated laminin α-chain expression in the cerebral cortex and eye of our FKRP knock-down mouse (FKRP(KD)). These mice showed a marked disturbance in the deposition of laminin α-chains including α1, α2, α4, and α5, although only laminin α1- and γ1-chain mRNA expression was significantly upregulated relative to controls. Moreover, there was a diffuse pattern of laminin deposition below the pial surface which correlated with an abrupt termination of many of the radial glial cells. This along with the pial basement membrane defects, contributed to the abnormal positioning of both early- and late-born neurons. Defects in the inner limiting membrane of the eye were associated with a reduction of laminin α1 demonstrating the involvement of the α-dystroglycan:laminin α1 axis in the disease process. These observations demonstrate for the first time that a reduction in Fkrp influences the ability of tissue-specific forms of α-dystroglycan to direct the deposition of several laminin isoforms in the formation of different basement membranes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900571      PMCID: PMC6623409          DOI: 10.1523/JNEUROSCI.2301-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  13 in total

1.  A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.

Authors:  Peter R Serafini; Michael J Feyder; Rylie M Hightower; Daniela Garcia-Perez; Natássia M Vieira; Angela Lek; Devin E Gibbs; Omar Moukha-Chafiq; Corinne E Augelli-Szafran; Genri Kawahara; Jeffrey J Widrick; Louis M Kunkel; Matthew S Alexander
Journal:  JCI Insight       Date:  2018-09-20

2.  Biochemical and biophysical changes underlie the mechanisms of basement membrane disruptions in a mouse model of dystroglycanopathy.

Authors:  Peng Zhang; Yuan Yang; Joseph Candiello; Trista L Thorn; Noel Gray; Willi M Halfter; Huaiyu Hu
Journal:  Matrix Biol       Date:  2013-02-27       Impact factor: 11.583

Review 3.  Fukutin-Related Protein: From Pathology to Treatments.

Authors:  Carolina Ortiz-Cordero; Karim Azzag; Rita C R Perlingeiro
Journal:  Trends Cell Biol       Date:  2020-12-01       Impact factor: 20.808

4.  Developmental disorders of the midbrain and hindbrain.

Authors:  A James Barkovich
Journal:  Front Neuroanat       Date:  2012-03-06       Impact factor: 3.856

Review 5.  A developmental and genetic classification for malformations of cortical development: update 2012.

Authors:  A James Barkovich; Renzo Guerrini; Ruben I Kuzniecky; Graeme D Jackson; William B Dobyns
Journal:  Brain       Date:  2012-03-16       Impact factor: 13.501

6.  Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.

Authors:  Atsushi Sudo; Motoi Kanagawa; Mai Kondo; Chiyomi Ito; Kazuhiro Kobayashi; Mitsuharu Endo; Yasuhiro Minami; Atsu Aiba; Tatsushi Toda
Journal:  Hum Mol Genet       Date:  2018-04-01       Impact factor: 6.150

7.  Degree of Cajal-Retzius Cell Mislocalization Correlates with the Severity of Structural Brain Defects in Mouse Models of Dystroglycanopathy.

Authors:  Helen S Booler; Josie L Williams; Mark Hopkinson; Susan C Brown
Journal:  Brain Pathol       Date:  2015-10-12       Impact factor: 6.508

8.  The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice.

Authors:  Charlotte Whitmore; Marta Fernandez-Fuente; Helen Booler; Callum Parr; Manoli Kavishwar; Attia Ashraf; Erica Lacey; Jihee Kim; Rebecca Terry; Mark R Ackroyd; Kim E Wells; Francesco Muntoni; Dominic J Wells; Susan C Brown
Journal:  Hum Mol Genet       Date:  2013-11-13       Impact factor: 6.150

9.  Prenatal muscle development in a mouse model for the secondary dystroglycanopathies.

Authors:  Jihee Kim; Mark Hopkinson; Manoli Kavishwar; Marta Fernandez-Fuente; Susan Carol Brown
Journal:  Skelet Muscle       Date:  2016-02-19       Impact factor: 4.912

10.  Transgenic Rescue of the LARGEmyd Mouse: A LARGE Therapeutic Window?

Authors:  J C W Hildyard; E Lacey; H Booler; M Hopkinson; D J Wells; S C Brown
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.